Salix Pharmaceuticals will buy Santarus for $32 per share in a transaction expected to close in the first quarter of 2014.
The per share price values Santarus at $2.6 billion, a 39 percent premium over the company's 30-day trading average.
The acquisition will help Salix solidify its lead in the gastrointestinal market, and the companies' combined revenue would be approximately $1.3 billion.
More Articles on Gastroenterology:
72% of Adults Have Not Sought Physician Help for GI Pain
Physicians Endoscopy Receives Cost Management Performance Award
Dr. Glenn Madokoro Gives GI Patients Access to Information Technology
The per share price values Santarus at $2.6 billion, a 39 percent premium over the company's 30-day trading average.
The acquisition will help Salix solidify its lead in the gastrointestinal market, and the companies' combined revenue would be approximately $1.3 billion.
More Articles on Gastroenterology:
72% of Adults Have Not Sought Physician Help for GI Pain
Physicians Endoscopy Receives Cost Management Performance Award
Dr. Glenn Madokoro Gives GI Patients Access to Information Technology